公开(公告)号：WO2019140370A1

公开(公告)日：2019-07-18

申请号：PCT/US2019/013468

申请日：2019-01-14

申请人： CHILDREN'S HOSPITAL MEDICAL CENTER

发明人： HILDEMAN, David, A. ,  ALMANAN, Maha ,  CHOUGNET, Claire, A.

IPC分类号： A61K39/00 ,  A61K39/395 ,  A61P31/00 ,  C07K16/24 ,  C07K16/28

CPC分类号： A61K39/145 ,  A61K39/00 ,  A61K39/3955 ,  A61K39/42 ,  A61K47/6913 ,  A61K47/6929 ,  A61K2039/505 ,  A61K2039/55 ,  A61P31/00 ,  A61P31/16 ,  C07K16/248 ,  C07K16/2827 ,  C07K16/2866 ,  C07K2317/76 ,  A61K2300/00

摘要： The disclosure provides methods for immunizing a subject in need thereof with a prophylactic vaccine against an infectious disease, the method comprising enhancing the subject's immune responsiveness to the vaccine by administering to the subject an agent that transiently inhibits IL-10 production by follicular helper T ("Tfh") cells.

公开(公告)号：WO2019109053A1

公开(公告)日：2019-06-06

申请号：PCT/US2018/063502

申请日：2018-11-30

申请人： JUNO THERAPEUTICS, INC.

发明人： ALBERTSON, Tina ,  HEIPEL, Mark D. ,  LI, He ,  SUTHERLAND, Claire L.

IPC分类号： A61K31/573 ,  C07K16/28 ,  A61P43/00 ,  G01N33/68

CPC分类号： A61K31/573 ,  A61K39/001112 ,  A61K39/39541 ,  A61K39/39558 ,  A61K48/0083 ,  A61K2039/505 ,  A61K2039/5156 ,  A61K2039/5158 ,  A61K2039/545 ,  A61K2039/55 ,  A61K2039/804 ,  A61P35/02 ,  A61P43/00 ,  C07K14/7051 ,  C07K14/70521 ,  C07K14/70578 ,  C07K14/71 ,  C07K16/2803 ,  C07K16/2866 ,  C07K2317/622 ,  C07K2319/03 ,  C07K2319/33 ,  C07K2319/40 ,  G01N33/6866 ,  G01N2333/7155 ,  A61K2300/00

摘要： Provided are methods of treatment, such as methods involving administering and/or determining dosing of, cell therapy, such as of cells engineered with a recombinant receptor, such as a T cell receptor (TCR) or chimeric antigen receptor (CAR). In some embodiments, the methods include determining a therapeutic range and/or window for dosing, for example, based on the estimated probabilities of risk of developing a toxicity and estimated probabilities of a treatment outcome or response, such as treatment, reduction nor amelioration of a sign or symptom thereof, or degree or durability thereof, following administration of the cell therapy or engineered cells. In some aspects, the methods involve administering an agent capable of modulating the engineered cells. Also provided are methods of ameliorating and/or treating a toxicity.

公开(公告)号：WO2019055955A1

公开(公告)日：2019-03-21

申请号：PCT/US2018/051418

申请日：2018-09-18

申请人： THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES

发明人： PASTAN, Ira H. ,  WEI, Junxia ,  ONDA, Masanori ,  BERA, Tapan ,  HO, Mitchell

IPC分类号： C07K16/28 ,  C07K16/30 ,  C07K14/21 ,  A61K47/68 ,  C07K19/00 ,  C12N15/62 ,  A61P35/00

CPC分类号： C07K16/30 ,  A61K47/6829 ,  A61K47/6849 ,  A61K47/6889 ,  C07K14/21 ,  C07K16/2803 ,  C07K16/2866 ,  C07K16/2878 ,  C07K2317/31 ,  C07K2317/569 ,  C07K2317/624 ,  C07K2317/73 ,  C07K2317/94 ,  C07K2319/32 ,  C07K2319/50 ,  C07K2319/55 ,  C07K2319/70

摘要： Disclosed is a molecule comprising: (a) a first domain, which comprises a targeting moiety; (b) a second domain, which comprises an albumin binding domain (ABD), (c) a third domain, which comprises a furin cleavage sequence ("FCS"), which FCS is cleavable by furin; and (d) a fourth domain, which comprises an optionally substituted Domain III from Pseudomonas exotoxin A ("PE"). Related nucleic acids, recombinant expression vectors, host cells, populations of cells, pharmaceutical compositions, methods of producing the molecule, methods of treating or preventing cancer in a mammal, and methods of inhibiting the growth of a target cell are also disclosed.

公开(公告)号：WO2018201130A1

公开(公告)日：2018-11-01

申请号：PCT/US2018/030153

申请日：2018-04-30

申请人： THE BRIGHAM AND WOMEN'S HOSPITAL, INC. ,  BRENNER, Michael

发明人： BRENNER, Michael ,  LYNCH, Lydia ,  KOHLGRUBER, Ayano

IPC分类号： A61K38/00 ,  A61K39/395 ,  A61P17/06 ,  A61P37/00 ,  C07K16/24

CPC分类号： A61P17/06 ,  A61K38/1774 ,  A61K38/1793 ,  A61K38/191 ,  A61K38/20 ,  A61K2039/505 ,  A61P37/00 ,  C07K16/241 ,  C07K16/244 ,  C07K16/2866 ,  C07K16/2878 ,  C07K2317/75 ,  C07K2317/76 ,  A61K2300/00

摘要： Methods of promoting or inhibiting weight loss by modulating activity levels of γδ T cells.

公开(公告)号：WO2018187642A1

公开(公告)日：2018-10-11

申请号：PCT/US2018/026381

申请日：2018-04-06

申请人： ABBVIE INC.

发明人： REILLY, Edward B. ,  ANDERSON, Mark G.

IPC分类号： A61K47/68 ,  A61P35/00

CPC分类号： C07K16/2866 ,  A61K47/6803 ,  A61K47/6849 ,  A61K47/6889 ,  A61P35/00 ,  C07K2317/24 ,  C07K2317/51 ,  C07K2317/515 ,  C07K2317/52

摘要： Provided are antibody drug conjugates that bind PRLR, in particular human PRLR, their methods of making, and uses thereof.

公开(公告)号：WO2018182527A1

公开(公告)日：2018-10-04

申请号：PCT/SG2018/050156

申请日：2018-03-29

申请人： NATIONAL UNIVERSITY OF SINGAPORE

发明人： SILVER, David Lawrence ,  WONG, Bernice Huimin

IPC分类号： A61K31/444 ,  C07K16/28 ,  A61K39/395 ,  A61P27/02

CPC分类号： A61K45/06 ,  A61K9/0048 ,  A61K31/444 ,  A61K2039/505 ,  A61P27/02 ,  C07K16/2866

摘要： The invention relates to methods of using inhibitors of CSF-1 R for reducing microglial activation in the eye as well as treating an inflammation associated with an eye disease, such as age-related macular degeneration (AMD), retinitis pigmentosa and diabetic retinopathy. The methods can further comprise the administration of anti-VEGF antibody. In preferred embodiments, the CSF-1 R inhibitor is Pexidartinib (PLX3397).

公开(公告)号：WO2018112033A1

公开(公告)日：2018-06-21

申请号：PCT/US2017/066097

申请日：2017-12-13

申请人： PRESIDENT AND FELLOWS OF HARVARD COLLEGE

发明人： BENOIST, Christophe ,  MATHIS, Diane ,  MAGNUSON, Angela ,  ERGUN, Ayla ,  WEISSLEDER, Ralph ,  KINER, Evgeny

IPC分类号： A61K39/395 ,  A61P35/00 ,  C07K16/28 ,  C12Q1/6886 ,  C12N15/113

CPC分类号： A61P35/00 ,  A61K2039/505 ,  C07K16/2866 ,  C07K16/2878 ,  C12N15/113 ,  C12N2310/20 ,  C12Q1/6886 ,  C12Q2600/158

摘要： Provided herein are methods and compositions related to the treatment or prevention of cancer (e.g., by targeting a tumor in a subject with cancer) by administering to a subject an agent disclosed herein. In certain aspects, the disclosure relates to targeting tumors in a subject, and/or decreasing the number of tumor infiltrating T regulatory cells (TITRs) (e.g., TITRs present within a tumor) in a subject by administering to the subject an agent disclosed herein. Further provided herein are methods of identifying anti-cancer agents that decrease the number or activity of TITRs in a subject or in a tumor present in a subject. In some aspects, provided herein are methods for identifying TITRs in a subject (e.g., identifying TITRs in a tumor present in a subject).

公开(公告)号：WO2018029182A1

公开(公告)日：2018-02-15

申请号：PCT/EP2017/070045

申请日：2017-08-08

申请人： ABLYNX N.V.

发明人： HOEFMAN, Sven ,  SARGENTINI-MAIER, Maria-Laura ,  VAN BENEDEN, Katrien

IPC分类号： C07K16/18 ,  C07K16/28 ,  A61K39/395 ,  A61K31/519

CPC分类号： C07K16/2866 ,  A61K31/519 ,  A61K39/395 ,  C07K16/18 ,  C07K2317/31 ,  C07K2317/569 ,  C07K2317/90 ,  A61K2300/00

摘要： Methods are provided for the treatment of IL-6R related diseases involving a combination therapy. More specifically, specific dose regimens and pre-filled syringes are provided for subcutaneous administration, to subjects suffering an IL-6R related disease, of immunoglobulin single variable domains that bind IL-6R, in combination with at least one additional therapeutic agent, such as methotrexate.

摘要翻译： 为涉及联合治疗的IL-6R相关疾病的治疗提供了方法。 更具体地说，提供了特定剂量方案和预填充注射器，用于皮下施用，患有IL-6R相关疾病的受试者，结合IL-6R的免疫球蛋白单可变结构域，与至少一种另外的治疗剂例如 氨甲蝶呤。

公开(公告)号：WO2017125578A1

公开(公告)日：2017-07-27

申请号：PCT/EP2017/051237

申请日：2017-01-20

申请人： VHSQUARED LIMITED

发明人： CROWE, Scott ,  CARLTON, Tim ,  CUBITT, Marion ,  ROBERTS, Kevin ,  MAGGIORE, Luana ,  WEST, Mike ,  RAY, Keith

IPC分类号： C07K16/28 ,  A61K39/395 ,  A61P29/00 ,  A61P1/00

CPC分类号： C07K16/2866 ,  A61K2039/505 ,  A61K2039/542 ,  C07K2317/22 ,  C07K2317/33 ,  C07K2317/565 ,  C07K2317/567 ,  C07K2317/569 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2317/94

摘要： There is provided inter alia a polypeptide comprising an immunoglobulin chain variable domain which binds to IL-6R, wherein the immunoglobulin chain variable domain comprises three complementarity determining regions (CDR1-CDR3) and four framework regions (FR1-FR4), wherein CDR1-CDR3 and FR1-FR4 are as defined in the specification.

摘要翻译： 特别提供了包含结合IL-6R的免疫球蛋白链可变结构域的多肽，其中免疫球蛋白链可变结构域包含三个互补决定区（CDR1-CDR3）和四个框架区（FR1 -FR4），其中CDR1-CDR3和FR1-FR4如说明书中所定义。

公开(公告)号：WO2017079369A3

公开(公告)日：2017-06-15

申请号：PCT/US2016060227

申请日：2016-11-03

申请人： GLAXOSMITHKLINE LLC

发明人： ZHOU HONGXING

IPC分类号： C07K16/00 ,  C07K16/18 ,  C07K16/42

CPC分类号： C07K16/2866 ,  C07K2317/24 ,  C07K2317/41 ,  C07K2317/52 ,  C07K2317/71 ,  C07K2317/76

摘要： Disclosed in this invention are human IgG Fc variants sequences that demonstrate low and no binding activities to Fc gamma receptor. The disclosed Fc variants are useful for making Fc fusion proteins and/or IgGs where low or no Fc effector function of the mentioned molecules are desirable.

摘要翻译： 本发明公开了对Fcγ受体表现出低且无结合活性的人IgG Fc变体序列。 所公开的Fc变体可用于制备Fc融合蛋白和/或IgG，其中所述分子的Fc效应子功能较低或不需要。